食品饮料/白酒Ⅱ 五粮液（000858.SZ） 2025 年 05 月 02 日 投资评级：买入（维持） | 日期 | 2025/4/30 | | --- | --- | | 当前股价(元) | 128.70 | | 一年最高最低(元) | 178.76/106.33 | | 总市值(亿元) | 4,995.63 | | 流通市值(亿元) | 4,995.44 | | 总股本(亿股) | 38.82 | | 流通股本(亿股) | 38.81 | | 近 3 个月换手率(%) | 32.17 | 股价走势图 数据来源：聚源 -36% -24% -12% 0% 12% 24% 2024-05 2024-09 2025-01 五粮液 沪深300 相关研究报告 《业绩稳健增长，彰显品牌韧性—公 司信息更新报告》-2024.9.1 《业绩稳健，核心矛盾明显改善—公 司信息更新报告》-2024.5.3 开局状态良好，渠道酝酿积极变化 ——公司信息更新报告 | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | ...

食品饮料/非白酒 百润股份（002568.SZ） 预调酒目标企稳增长，威士忌业务推进顺利 2025 年 05 月 02 日 投资评级：增持（维持） | 日期 | 2025/4/30 | | --- | --- | | 当前股价(元) | 26.10 | | 一年最高最低(元) | 31.70/15.00 | | 总市值(亿元) | 273.89 | | 流通市值(亿元) | 187.39 | | 总股本(亿股) | 10.49 | | 流通股本(亿股) | 7.18 | | 近 3 个月换手率(%) | 82.73 | 股价走势图 数据来源：聚源 -40% -20% 0% 20% 40% 60% 2024-04 2024-08 2024-12 2025-04 百润股份 沪深300 相关研究报告 《预调酒销售持续承压，期待业绩逐 步改善 — 公 司 信 息 更 新 报 告 》 -2024.11.3 《预调酒销售短期承压，下半年新品 值 得 期 待 — 公 司 信 息 更 新 报 告 》 -2024.8.1 《预调酒业务行稳致远，威士忌新品 前 景 可 期 — 公 司 首 次 覆 盖 报 告 》 -2024.7. ...

Investment Rating - The investment rating for the company is "Buy" [4][8][20] Core Views - The company reported strong performance in Q1 2025, with revenue of 82.2 billion yuan, a year-on-year increase of 30.2%, and a net profit of 3.2 billion yuan, up 17.3% year-on-year. This growth is attributed to the high demand for gold and jewelry in Beijing, where the company has a significant presence [1] - The company benefits from a high proportion of revenue from precious metal investment products, which saw a strong demand in Q1 2025 due to rising gold prices [1] - The company plans to expand its brand influence through an omnichannel strategy, combining online and offline sales [4] Financial Performance - In 2024, the company expects revenue of 202 billion yuan, a 22.2% year-on-year increase, and a net profit of 7.2 billion yuan, a 1.7% increase year-on-year [1] - The company plans to distribute a cash dividend of 7.20 yuan per 10 shares, with a dividend payout ratio of 77.9% [2] - The revenue from precious metal investment products is expected to grow by 45.3% in 2024, while gold jewelry sales are projected to decline by 11.1% [3] - The company opened 20 new direct stores in 2024, with plans for further expansion in 2025 [3] Financial Projections - The projected net profit for 2025 is 7.9 billion yuan, with corresponding P/E ratios of 14, 12, and 11 for 2025, 2026, and 2027 respectively [4] - The company’s revenue is expected to grow from 16.55 billion yuan in 2023 to 31.87 billion yuan by 2027, reflecting a compound annual growth rate [6][14] - The gross margin for 2024 is projected to be 8.9%, with a net margin of 3.6% [3][14]

Investment Rating - The investment rating for the company is "Accumulate" [8] Core Views - The company reported a total revenue of 1.297 billion yuan in 2024, a year-on-year increase of 1.51%, and a net profit attributable to shareholders of 92.52 million yuan, a decrease of 46.86% year-on-year [8] - The company focuses on Southeast Asia and the Middle East, leveraging 20 years of experience to enhance customer loyalty and pursue high-quality orders, achieving 72 new projects worth 2.05 billion yuan in 2024, a 93% increase year-on-year [8] - The company is expected to benefit from its innovative technology and comprehensive geotechnical engineering services, with a second growth curve driven by perovskite materials [8] Financial Summary - Total revenue forecast for 2025 is 2 billion yuan, with a year-on-year growth of 54.24% [8] - The net profit forecast for 2025 is 252.11 million yuan, reflecting a significant recovery from the previous year's decline [8] - The company's comprehensive gross margin for 2024 was 29.6%, down 4.7 percentage points year-on-year, with a net profit margin of 6.7%, down 6.6 percentage points year-on-year [8] - The company’s cash flow from operating activities was -83 million yuan in 2024, a decline of 217 million yuan year-on-year [8] - The asset-liability ratio at the end of 2024 was 22.4%, an increase of 3.1 percentage points year-on-year [8]

公司报告 | 季报点评 报喜鸟（002154） 证券研究报告 费用增长致业绩短期承压 公司发布一季报 （4）所罗：坚持高级定制不动摇，积极拓展加盟渠道，聚焦核心品类定制， 加强督导对终端店铺的指导和培训，提升店铺运营能力。 成长品牌聚焦细分赛道，升级单店模型，提高顾客认知快速增长 （1）乐飞叶：坚持"法国百年户外"的专业户外定位，叠加"女性友好" 概念，通过差异化的定位实现"小众破圈"。 25Q1 公司营收 13 亿同减 4%，归母净利 1.7 亿同减 32%，扣非后归母净利 1.6 亿同减 30%。 本期管理费用同增 26%，系 24 年内公司收购 Woolrich 品牌产生的相关费 用、品牌咨询服务费用及无形资产摊销、人工成本费用增加，上海松江工 业园、合肥工业园投入使用产生的折旧费较上年同期增长所致。 财务费用同增 82.24%，系一季度银行存款减少且利率下降导致利息收入较 上年同期减少所致。 资产减值损失-0.3 亿，系一季度公司营业收入小幅下滑，费用率上升，导 致存货计提减值增加所致。 成熟品牌坚持高标准对标品牌，以系统化的"四力"提升为基础，以关键 战役为突破口，提升品牌势能，保持各自细分赛道领先 ...

公司报告 | 季报点评 科兴制药（688136） 证券研究报告 2025Q1 海外收入持续增长，创新平台进入收获期 2024 年海外收入 2.24 亿元，同比增长约 61.96%。根据股权激励，2025 年 海外收入相较 2023 年的目标增速为 200%-400%，预计为 4.15-6.92 亿元。 科兴制药海外销售渠道已经覆盖七十多个国家和地区，在巴西、墨西哥、 新加坡、德国、越南、埃及等地设立了子公司，覆盖欧州、中南美、东南 亚、中东北非等区域。目前已引进 10 余款重磅药物的海外商业化权益， 近期，引进的产品阿达木单抗和贝伐珠单抗已分别获得沙特和巴西等地的 GMP 证书。公司于 2024 年引进的九源基因的司美格鲁肽生物类似物，其 有望于 2025 年在国内获批上市，科兴制药已同步开展海外上市准入的准 备工作，预计于 2025 年向巴西 ANVISA 递交 NDA。近期，公司与科伦药 业、海创药业等公司签署战略合作，进一步扩大公司海外业务拓展基础。 事件 近日，公司发布 2024 年年报和 2025 年第一季度报告。公司 2024 年全年 营业收入为 14.07 亿元，同比增长 11.75%，归母净利 ...

长盛轴承(300718)公司点评报告 2025 年 05 月 02 日 [Table_Main] 公司研究|工业|资本货物 证券研究报告 [Table_Title] Q1 稳健增长，关注机器人轴承及丝杠产品 ——长盛轴承 2024 年年度报告及 2025 年一季报点评 [Table_Summary] 事件： 公司发布 2024 年年报：2024 年公司营收 11.37 亿元，同比增长 2.89%； 实现归母净利润/扣非归母净利润分别为 2.29/2.12 亿元，同比分别变动- 5.43%/-4.22%。其中，Q1-4 公司分别实现营收 2.76/2.81/2.78/3.02 亿 元，同比分别变动 6.85%/1.49%/-2.06%/5.61%。 公司发布 2025 年一季度报告：2025 年 Q1 单季度公司实现营收 2.82 亿元， 同比增长 2.18%；实现归母净利润/扣非归母净利润分别为 0.53/0.50 亿 元，同比分别变动 1.54%/1.50%。 汽车下游稳健增长助推公司主业，国内业务提供增量 根据中国汽车工业协会数据，2024 年汽车产销累计完成 3128.2 万辆和 3143.6 万辆，同 ...

Investment Rating - The investment rating for the company is "Buy" and it is maintained [5][16]. Core Views - The company reported a steady growth in HIV revenue, with a first-quarter revenue of 198 million yuan in 2025, representing a year-on-year increase of 113% [1]. - The company’s HIV product, AINOMITE tablets, has advantages in convenience and is expected to continue to grow in sales in 2025, with first-quarter revenue of 62.72 million yuan, a 76% increase year-on-year [2]. - The company has a deep layout in the HIV drug field, with two key products under development, including the integrase inhibitor ACC017, which is expected to enter Phase III clinical trials this year [3]. Financial Performance - In 2024, the company achieved an operating income of 418 million yuan, a year-on-year increase of 1.57%, while the net profit attributable to the parent company was -141 million yuan, a year-on-year increase in loss of 85.63% [1]. - The expected operating income for 2025 has been revised down from 808 million yuan to 732 million yuan, with projected revenues of 1.022 billion yuan and 1.235 billion yuan for 2026 and 2027, respectively [4]. - The net profit attributable to the parent company for 2025-2026 has been adjusted from 16 million yuan and 84 million yuan to -10 million yuan and 37 million yuan, respectively, with an expected net profit of 79 million yuan in 2027 [4]. Market Position - The company’s AINOMITE tablets are the first domestic three-in-one single-tablet combination with independent intellectual property rights, showing better cardiovascular safety compared to competitors [2]. - The company is positioned in a competitive market for HIV treatments, with ongoing research and development efforts aimed at innovative long-acting drugs [3].

Investment Rating - The report maintains a "Buy" rating for the company, considering the potential for significant returns over the next six months [5][8]. Core Views - The semiconductor industry is returning to a growth trajectory, and the company's performance is steadily improving, with a revenue increase of 20.16% year-on-year to 2.596 billion yuan in 2024 [2][5]. - The company is focusing on AIoT smart modules, automotive electronics, and audio sensors, establishing a differentiated competitive advantage in these areas [2][3]. - The company has invested in the National Intelligent Sensor Innovation Center to enhance its AIoT chip business and edge computing capabilities, aiming to develop integrated sensing and computing solutions [3][4]. Financial Performance Summary - In 2024, the company achieved a net profit attributable to shareholders of 36.37 million yuan, a year-on-year increase of 2.07%, while the non-recurring net profit was 35 million yuan, up 10.17% [1][2]. - The first quarter of 2025 saw a revenue of 586 million yuan, reflecting a 5.96% year-on-year growth, with a net profit of 13 million yuan [1][2]. - The company forecasts a net profit of 154 million yuan for 2025, with a significant growth rate of 322.37% expected in 2026 [5][6]. Business Development Summary - The company is advancing both customized and self-developed chip businesses, achieving sales of 176 million yuan in 2024, a growth of 42.22% [4]. - Collaborations with upstream semiconductor design firms are ongoing to develop wireless smart appliance chips and AI glasses SOC chips [4]. - The partnership with Qiyimoer focuses on Chiplet interconnects and AI computing chips, enhancing technological innovation and business expansion [4].

Investment Rating - The investment rating for the company is "Accumulate" [1] Core Views - The company reported a total revenue of 1.297 billion yuan in 2024, a year-on-year increase of 1.51%, while the net profit attributable to shareholders was 0.9252 billion yuan, a decrease of 46.86% year-on-year [8] - The company has focused on Southeast Asia and the Middle East, leveraging its 20 years of experience to secure high-quality orders, with 72 new projects signed in 2024 amounting to 2.05 billion yuan, a year-on-year increase of 93% [8] - The company is experiencing a temporary drag due to upfront expenses, but the long-term outlook remains positive due to dual growth drivers [8] Financial Summary - Total revenue forecast for 2025 is 2 billion yuan, with a year-on-year growth of 54.24% [1] - The net profit forecast for 2025 is 0.2521 billion yuan, reflecting a significant recovery from the previous year's decline [1] - The company's comprehensive gross margin for 2024 was 29.6%, a decrease of 4.7 percentage points year-on-year, with domestic and international gross margins at 20.3% and 31% respectively [8] - The company’s cash flow from operating activities was -0.83 billion yuan in 2024, a decline of 2.17 billion yuan year-on-year [8] - The asset-liability ratio at the end of 2024 was 22.4%, an increase of 3.1 percentage points year-on-year [8]